Literature DB >> 15610604

Targeted adenovirus vectors.

Hiroyuki Mizuguchi1, Takao Hayakawa.   

Abstract

Recombinant adenovirus (Ad) vectors continue to be the preferred vectors for gene therapy and the study of gene function because they are relatively easy to construct, can be produced at high titer, and have high transduction efficiency. However, in some applications gene transfer with Ad vectors is less efficient because the target cells lack expression of the primary receptor, coxsackievirus and adenovirus receptor (CAR). Another problem is the wide biodistribution of vector in tissue following in vivo gene transfer because of the relatively broad tissue expression of CAR. To overcome these limitations, various approaches have been developed to modify Ad tropism. In one approach, the capsid proteins of Ad are modified, such as with the addition of foreign ligands or the substitution of the fiber with other types of Ad fiber, in combination with the ablation of native tropism. In other approaches, Ad vectors are conjugated with adaptor molecules, such as antibody and fusion protein containing an anti-Ad single-chain antibody (scFv) or the extracellular domain of CAR with the targeting ligands, or chemically modified with polymers containing the targeting ligands. In this paper, we review advances in the development of targeted Ad vectors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15610604     DOI: 10.1089/hum.2004.15.1034

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  41 in total

Review 1.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

Authors:  Jaesung Kim; Pyung-Hwan Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

Review 2.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

3.  DRG-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice.

Authors:  Tomoya Terashima; Kazuhiro Oka; Angelika B Kritz; Hideto Kojima; Andrew H Baker; Lawrence Chan
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

4.  Immune safety of a novel oncolytic mutant M1 after administration in vivo.

Authors:  Lijun Jiang; Xiaoxi Zhou; Qinlu Li; Fei Yu; Liang Huang; Quanfu Ma; Jianfeng Zhou; Yang Cao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-08-11

5.  Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy.

Authors:  Xinglei Yao; Yasuo Yoshioka; Tomohiro Morishige; Yusuke Eto; Shogo Narimatsu; Yasuaki Kawai; Hiroyuki Mizuguchi; Jian-Qing Gao; Yohei Mukai; Naoki Okada; Shinsaku Nakagawa
Journal:  Mol Ther       Date:  2011-06-14       Impact factor: 11.454

Review 6.  MicroRNA-regulated viral vectors for gene therapy.

Authors:  Anja Geisler; Henry Fechner
Journal:  World J Exp Med       Date:  2016-05-20

7.  Ex-vivo evaluation of gene therapy vectors in human pancreatic (cancer) tissue slices.

Authors:  Michael-A van Geer; Koert F D Kuhlmann; Conny T Bakker; Fibo J W ten Kate; Ronald P J Oude Elferink; Piter J Bosma
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

8.  Surface immobilization of hexa-histidine-tagged adeno-associated viral vectors for localized gene delivery.

Authors:  J-H Jang; J T Koerber; K Gujraty; S R Bethi; R S Kane; D V Schaffer
Journal:  Gene Ther       Date:  2010-05-27       Impact factor: 5.250

9.  Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smooth muscle and endothelial cells.

Authors:  Michael Chorny; Ilia Fishbein; Ivan Alferiev; Robert J Levy
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

10.  Affinity thresholds for membrane fusion triggering by viral glycoproteins.

Authors:  Kosei Hasegawa; Chunling Hu; Takafumi Nakamura; James D Marks; Stephen J Russell; Kah-Whye Peng
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.